Bluebird Bio (BLUE) said Friday it agreed to be acquired by Carlyle Group (CG) managed funds and SK Capital Partners.
Under the terms of the deal, bluebird shareholders will receive $3.00 per share in cash and a contingent value of $6.84 per share, payable in cash if bluebird's current product portfolio earns $600 million in net sales in any trailing 12-month period before or ending on Dec. 31, 2027.
Shares slumped 41% following a surge in intraday trading volume to over 4.5 million from a daily average of about 392,000.
AXT (AXTI) reported a wider Q4 non-GAAP loss late Thursday compared with a year ago and sequentially. Wedbush adjusted AXT's price target to $4.50 from $5.50 while maintaining its outperform rating.
Shares of AXT sank 31%, with intraday trading volume catapulting to over 5.3 million versus a daily average of about 361,000.
Akamai Technologies (AKAM) has "limited" short-term growth opportunities, BofA Securities said in a note Friday, following the company's Q4 results overnight. BofA downgraded Akamai to neutral from buy and cut its price target to $100 from $125.
Shares fell 20%, with intraday trading volume surging to over 13.6 million versus a daily average of about 1.7 million.
Price: 4.15, Change: -2.90, Percent Change: -41.12
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。